The change in organ specific insulin sensitivity after treatment of endocrine and metabolic disorder

The change in organ specific insulin sensitivity after treatment of endocrine and metabolic disorder - The change in organ specific insulin sensitivity after treatment of endocrine and metabolic disorder

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033791

Enrollment

100

Registered

2018-08-17

Start date

2018-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endocrine and metabolic disorder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who is diagnosed endocrinological disease Patients whose content is obtained in written form

Exclusion criteria

Exclusion criteria: Younger than 20 years old Pregnant or lactating women Patient in endocrinological emergency Severe mental problems not suitable for the study Inability to participate in the study as assessed by the investigators.

Design outcomes

Primary

Measure	Time frame
Changes from baseline in organ specific insulin sensitivity and glucagon response during a euglycemic hyperinsulinemic clamp study	—

Secondary

Measure	Time frame
1Change from baseline in fasting plasma glucose level and glucose metabolism assessed with arginine tolerance test 2Change from baseline in body composition 3Change from baseline in vital sign 4Change from baseline in hormone levels of endocrine and metabolic disorder 5Change from baseline in medication 6Change from baseline in liver function 7Changes from baseline in lipid profile 8Changes from baseline in renal function and electrolyte balance 9Changes from baseline in hepatokine levels 10Changes from baseline in oxidative and non-oxidative glucose disposal, respiratory quotients, and energy expenditure	—

Measure

Time frame

1Change from baseline in fasting plasma glucose level and glucose metabolism assessed with arginine tolerance test 2Change from baseline in body composition 3Change from baseline in vital sign 4Change from baseline in hormone levels of endocrine and metabolic disorder 5Change from baseline in medication 6Change from baseline in liver function 7Changes from baseline in lipid profile 8Changes from baseline in renal function and electrolyte balance 9Changes from baseline in hepatokine levels 10Changes from baseline in oxidative and non-oxidative glucose disposal, respiratory quotients, and energy expenditure

—

Countries

Japan

Contacts

Public ContactYumie Takeshita

Kanazawa university hospital Department of Endocrinology and metabolism

takeshita@m-kanazawa.jp076-265-2234

Outcome results